Slowing myopia progression with a novel spectacle lens - 1-year, randomized double-masked, cross-over clinical trial.

Myopia progression was significantly slower with test spectacle during both stages.

During stage II, myopia progressed slower by 0.25D (0.15, 0.36) and 0.11 mm (0.07, 0.14) (P < 0.001) with test spectacle.

Progression with single vision during stage I and stage II did not differ significantly (SE: -0.42 ± 0.31D vs -0.51 ± 0.30D, p = 0.119; AL: 0.19 ± 0.11 mm vs 0.22 ± 011 mm, P = 0.182).